1. Signaling Pathways
  2. Immunology/Inflammation
  3. CD2

CD2 

Cluster of differentiation 2

CD2 是一种主要在 T 细胞、自然杀伤细胞(NK)和胸腺细胞表面表达的跨膜糖蛋白,属于免疫球蛋白超家族。它与细胞表面的 LFA-3 结合,在免疫反应中发挥重要作用,尤其是在免疫突触的形成与组织中。CD2 通过与 LFA-3 的结合促进 T 细胞的激活,从而增强免疫反应。CD2 在记忆 T 细胞和活化 T 细胞中的表达上调,对于记忆 T 细胞的激活至关重要。
CD2 在调控免疫细胞功能方面也起着重要作用,尤其是在器官移植和某些自身免疫疾病中。通过抑制 CD2/LFA-3 共刺激通路,CD2 能减少过度激活的 T 细胞和 NK 细胞,从而降低移植物排斥的风险并延长移植物的存活期。此外,研究还表明,CD2 在 NK 细胞的自发性细胞毒性及某些癌症免疫反应中也发挥着关键作用。因此,CD2 作为免疫调节靶点具有广阔的应用前景,特别是在研究自身免疫疾病和促进器官移植免疫耐受方面[1]

CD2 is a transmembrane glycoprotein primarily expressed on the surface of T cells, natural killer (NK) cells, and thymocytes, belonging to the immunoglobulin superfamily. It binds to LFA-3 on the cell surface and plays an important role in immune responses, especially in the formation and organization of the immunological synapse. CD2 enhances T cell activation by binding to LFA-3, thereby boosting immune responses. The expression of CD2 is upregulated on memory T cells and activated T cells, playing a crucial role in the activation of memory T cells.
CD2 also plays a significant role in regulating immune cell functions, particularly in organ transplantation and certain autoimmune diseases. By inhibiting the CD2/LFA-3 co-stimulatory pathway, CD2 can reduce the excessive activation of T cells and NK cells, thereby lowering the risk of graft rejection and prolonging graft survival. Additionally, research indicates that CD2 plays a critical role in NK cell spontaneous cytotoxicity and certain cancer immune responses. Therefore, CD2 presents a broad application potential as an immune-regulatory target, especially in the study of autoimmune diseases and promoting immune tolerance in organ transplantation.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P99904
    Siplizumab Inhibitor 99.83%
    Siplizumab (MEDI-507) 是一种抗 CD2 的人源化 IgG1 单克隆抗体。Siplizumab 可耗尽 T 细胞、降低 T 细胞活化、抑制 T 细胞增殖并富集 naïvebona fide 调节性 T 细胞。
    Siplizumab
  • HY-P99757
    Nivatrotamab Inhibitor 99.40%
    Nivatrotamab (Hu3F8-BsAb) 是一种人源化抗 GD2/CD3 双特异性抗体。 Nivatrotamab 是一种基于 CD3 和 GD2 特异性 bsAb 的 T 细胞接合剂 Nivatrotamab 可用于神经母细胞瘤的研究。
    Nivatrotamab
  • HY-158109
    M3554 99.39%
    M3554 是基于人源化 ch14.18 抗 GD2 抗体设计的新型抗 GD2 ADC,具有抗肿瘤活性。M3554 对 GD2 阳性神经母细胞瘤细胞系 CHP134 的细胞毒性处于亚纳摩尔 IC50 范围内。
    M3554
  • HY-P990868
    Anti-CD2 Antibody (CB.219) Inhibitor
    Anti-CD2 Antibody (CB.219) 是小鼠 IgG2b, κ 嵌合抗体,靶向 CD2 (人源)。Anti-CD2 Antibody (CB.219) 的同型对照为 Mouse IgG2b kappa, Isotype Control (HY-P99982)。
    Anti-CD2 Antibody (CB.219)
  • HY-P990286
    Anti-Rat CD2 Antibody (OX-34)
    Anti-Rat CD2 Antibody (OX-34) 是抗大鼠 CD2 的 抗体抑制剂。
    Anti-Rat CD2 Antibody (OX-34)
目录号 产品名 / 同用名 应用 反应物种